Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological...
LeukemiaMyeloid14 moreThe purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory...
Multiple MyelomaTo evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Acute LeukemiaAcute Lymphoblastic Leukemia2 moreChromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.
Stem Cell Translpantation in Multiple Myeloma
Multiple MyelomaThe purpose of this study is to determine whether autologous transplantation (using the patient's own stem cells from the blood), followed by non-myeloablative (i.e. less intense) allogeneic transplantation (where the blood stem cells from a sibling donor are used for the transplantation) improves the outcome in patients with newly diagnosed multiple myeloma.
The clonoSEQ® Watch Registry
Acute Lymphoblastic LeukemiaAdult B-Cell3 moreThis is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
Multiple MyelomaAcute Myeloid Leukemia10 moreThe purpose of this study is to see whether hematopoietic stem cell transplant (HSCT) patients can consistently eat a diet rich in prebiotics. This type of diet may be helpful in maintaining diversity in the gastrointestinal (GI) system and therefore potentially decreasing risk of other GI problems.
COVID-19 Infection and Multiple Myeloma
Multiple MyelomaCovid191 moreCollect in an observational study the outcomes of COVID19 infection in MM patients across Europe.
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual...
Myeloma MultipleTo assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease...
Multiple MyelomaAmyloidosisThis pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. The primary objectives of this study are to assess renal allograft tolerance (that is, the acceptance of the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in multiple myeloma and AL amyloidosis, and assess complication rates for genetically (HLA) matched related donor combined bone marrow and kidney transplantation using a low dose total body irradiation based preparative regimen.
Blood Samples to Identify Biomarkers of Busulfan
LeukemiaLymphoma3 moreSpecific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance. Specific Aim 2: To characterize IV BU metabolism by metabolomics. Specific Aim 3: To identify covariates influencing IV BU pharmacokinetics.